Form 4: Director Ali Behbahani Acquires Black Diamond Therapeutics Options

Director Ali Behbahani of Black Diamond Therapeutics, Inc. acquired stock options for 40,000 shares, with vesting contingent on continued service.

Summary

• Director Ali Behbahani acquired a stock option to purchase 40,000 shares of Black Diamond Therapeutics, Inc. common stock.
• The option has an exercise price of $1.71 per share.
• The shares subject to the option will vest in full on the earlier of June 26, 2027, or the Issuer's next annual meeting of stockholders, provided Mr. Behbahani continues to serve as a director.
• The transaction date was June 26, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a standard incentive grant to a director, indicating continued engagement rather than a significant strategic shift or financial event.

Positives

• Director's acquisition of stock options signals confidence in the company's future prospects.
• The option grant provides a potential incentive for continued service and alignment with shareholder interests.

Risks

• The vesting of the options is contingent on continued service, meaning the director could forfeit them if they leave the company before the vesting date.
• The value of the options is tied to the future performance of Black Diamond Therapeutics' stock price.

Future Outlook

The vesting schedule for the acquired stock options indicates a forward-looking commitment from the director, tied to the company's performance and the director's continued tenure.

Industry Context

StockSavvy.ai notes that the acquisition of stock options by a director is a common practice in the biotechnology sector, often used as a long-term incentive to align management and board members with shareholder value creation.

Stakeholder Impact

• Shareholders: The option grant aligns director incentives with long-term shareholder value, but the actual impact depends on the company's future stock performance.

Next Steps

• Director Ali Behbahani will continue to serve on the board.
• The stock options will vest on the specified dates, subject to continued service.

Key Dates

Keywords

Black Diamond Therapeutics, BDTX, Form 4, Stock Options, Director, Beneficial Ownership, SEC Filing, Insider Trading